PL1765362T3 - Kompozycje i sposoby do leczenia chorób związanych z neowaskularyzacją - Google Patents
Kompozycje i sposoby do leczenia chorób związanych z neowaskularyzacjąInfo
- Publication number
- PL1765362T3 PL1765362T3 PL05804888T PL05804888T PL1765362T3 PL 1765362 T3 PL1765362 T3 PL 1765362T3 PL 05804888 T PL05804888 T PL 05804888T PL 05804888 T PL05804888 T PL 05804888T PL 1765362 T3 PL1765362 T3 PL 1765362T3
- Authority
- PL
- Poland
- Prior art keywords
- signaling inhibitor
- compositions
- methods
- neovascular diseases
- trprs
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 101000640990 Arabidopsis thaliana Tryptophan-tRNA ligase, chloroplastic/mitochondrial Proteins 0.000 abstract 4
- 102000002501 Tryptophan-tRNA Ligase Human genes 0.000 abstract 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 4
- 230000011664 signaling Effects 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000000964 angiostatic effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 230000006459 vascular development Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12Y601/01002—Tryptophan-tRNA ligase (6.1.1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57715604P | 2004-06-04 | 2004-06-04 | |
| US58527304P | 2004-07-01 | 2004-07-01 | |
| US65580105P | 2005-02-24 | 2005-02-24 | |
| EP05804888A EP1765362B1 (en) | 2004-06-04 | 2005-06-06 | Compositions and methods for treatment of neovascular diseases |
| PCT/US2005/019800 WO2005117954A2 (en) | 2004-06-04 | 2005-06-06 | Compositions and methods for treatment of neovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1765362T3 true PL1765362T3 (pl) | 2012-08-31 |
Family
ID=35463352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12002028T PL2484365T3 (pl) | 2004-06-04 | 2005-06-06 | Kompozycje i sposoby leczenia chorób neowaskularnych |
| PL05804888T PL1765362T3 (pl) | 2004-06-04 | 2005-06-06 | Kompozycje i sposoby do leczenia chorób związanych z neowaskularyzacją |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12002028T PL2484365T3 (pl) | 2004-06-04 | 2005-06-06 | Kompozycje i sposoby leczenia chorób neowaskularnych |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7528106B2 (pl) |
| EP (3) | EP2484364B1 (pl) |
| JP (1) | JP4943324B2 (pl) |
| KR (1) | KR101224368B1 (pl) |
| AT (1) | ATE551060T1 (pl) |
| AU (1) | AU2005249586B2 (pl) |
| CA (1) | CA2568750C (pl) |
| DK (2) | DK2484365T3 (pl) |
| ES (3) | ES2382661T3 (pl) |
| MX (1) | MXPA06014092A (pl) |
| PL (2) | PL2484365T3 (pl) |
| PT (2) | PT1765362E (pl) |
| WO (1) | WO2005117954A2 (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1765362E (pt) * | 2004-06-04 | 2012-06-04 | Scripps Research Inst | Composições e métodos para o tratamento de doenças neovasculares |
| US8282921B2 (en) * | 2004-08-02 | 2012-10-09 | Paul Glidden | tRNA synthetase fragments |
| US20060024288A1 (en) * | 2004-08-02 | 2006-02-02 | Pfizer Inc. | tRNA synthetase fragments |
| KR101244202B1 (ko) * | 2005-02-24 | 2013-03-18 | 더 스크립스 리서치 인스티튜트 | 허혈성 망막 조직의 혈관재형성 및 이의 스크리닝 방법 |
| ES2338400B1 (es) * | 2008-05-06 | 2011-09-14 | David Benet Ferrus | Conjunto de moleculas antiangiogenicas y su uso. |
| MX2010013632A (es) | 2008-06-11 | 2011-06-16 | Atyr Pharma Inc | Actividad trombopoyetica de polipeptidos de tirosil-arnt sintetasa. |
| EP2310498A1 (en) | 2008-06-26 | 2011-04-20 | Atyr Pharma, Inc. | Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities |
| US20120004185A1 (en) | 2009-02-27 | 2012-01-05 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
| US8370736B2 (en) * | 2009-03-16 | 2013-02-05 | Apple Inc. | Methods and graphical user interfaces for editing on a multifunction device with a touch screen display |
| DK2408905T3 (en) | 2009-03-16 | 2017-08-28 | Pangu Biopharma Ltd | Compositions and Methods comprising Histidyl-tRNA Synthetase Splicing Variants with Non-Canonical Biological Activities |
| WO2010120509A2 (en) | 2009-03-31 | 2010-10-21 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities |
| WO2011072266A2 (en) * | 2009-12-11 | 2011-06-16 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating hematopoiesis |
| US8828395B2 (en) | 2009-12-11 | 2014-09-09 | Atyr Pharma, Inc. | Antibodies that bind tyrosyl-tRNA synthetases |
| DK2509625T3 (en) | 2009-12-11 | 2015-04-27 | Atyr Pharma Inc | Histidyl tRNA synthetases to reduce inflammation |
| US8980253B2 (en) | 2010-04-26 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
| EP2563381B1 (en) | 2010-04-27 | 2017-08-09 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases |
| CN103096910A (zh) | 2010-04-27 | 2013-05-08 | Atyr医药公司 | 与苏氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CN103097524B (zh) | 2010-04-28 | 2016-08-03 | Atyr医药公司 | 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CN103097523B (zh) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| EP2563383B1 (en) | 2010-04-29 | 2017-03-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
| WO2011150279A2 (en) | 2010-05-27 | 2011-12-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
| US8981045B2 (en) | 2010-05-03 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
| CA2797277C (en) | 2010-05-03 | 2021-02-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
| ES2623805T3 (es) | 2010-05-03 | 2017-07-12 | Atyr Pharma, Inc. | Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas |
| JP6039546B2 (ja) | 2010-05-03 | 2016-12-07 | エータイアー ファーマ， インコーポレイテッド | セリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| CA2798301C (en) | 2010-05-04 | 2020-09-15 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-trna synthetases |
| CA2798139C (en) | 2010-05-04 | 2019-09-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
| WO2011143482A2 (en) | 2010-05-14 | 2011-11-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
| WO2011146410A2 (en) | 2010-05-17 | 2011-11-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases |
| CA2800281C (en) | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
| EA030418B1 (ru) | 2010-07-12 | 2018-08-31 | ЭйТИР ФАРМА, ИНК. | ТЕРАПЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНОГО ЗАБОЛЕВАНИЯ, ПОЛИПЕПТИД АМИНОАЦИЛ-тРНК-СИНТЕТАЗЫ (AARS) |
| US8969301B2 (en) | 2010-07-12 | 2015-03-03 | Atyr Pharma Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases |
| US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| CN103118695B (zh) | 2010-07-12 | 2016-08-03 | Atyr医药公司 | 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现 |
| AU2011293294B2 (en) | 2010-08-25 | 2016-03-24 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases |
| AU2011311956C1 (en) * | 2010-10-06 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases |
| US9714419B2 (en) | 2011-08-09 | 2017-07-25 | Atyr Pharma, Inc. | PEGylated tyrosyl-tRNA synthetase polypeptides |
| US9822353B2 (en) | 2011-12-06 | 2017-11-21 | Atyr Pharma, Inc. | PEGylated aspartyl-tRNA synthetase polypeptides |
| US9816084B2 (en) | 2011-12-06 | 2017-11-14 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetases |
| US9688978B2 (en) | 2011-12-29 | 2017-06-27 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetase-Fc conjugates |
| EP3311847A1 (en) | 2012-02-16 | 2018-04-25 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
| WO2014145050A1 (en) | 2013-03-15 | 2014-09-18 | Atyr Pharma, Inc. | Histidyl-trna synthetase-fc conjugates |
| ES2949987T3 (es) * | 2015-02-26 | 2023-10-04 | Mirimgene Co Ltd | Composición para el tratamiento o la prevención de enfermedad inflamatoria infecciosa o composición para la mejora inmunitaria, que comprende triptofanil-ARNt sintetasa como principio activo |
| EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
| WO2023001288A1 (zh) * | 2021-07-23 | 2023-01-26 | 百奥泰生物制药股份有限公司 | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 |
| CN116515827B (zh) * | 2023-03-20 | 2024-12-10 | 复旦大学附属眼耳鼻喉科医院 | 用于治疗年龄相关性黄斑变性的活性成分、药物组合物和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4405378A1 (de) | 1994-02-19 | 1995-08-24 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| DE4415310A1 (de) | 1994-04-30 | 1995-11-02 | Merck Patent Gmbh | Cyclopeptide |
| DE4429461A1 (de) | 1994-08-19 | 1996-02-22 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| EP0710657B1 (de) | 1994-11-02 | 1998-08-26 | MERCK PATENT GmbH | Adhäsionsrezeptor-Antagonisten |
| DE19516483A1 (de) | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| EP2298300A1 (en) * | 1996-11-05 | 2011-03-23 | The Children's Medical Center Corporation | Compositions for inhibition of anglogenesis comprising thalidomide and aspirin |
| US6559144B2 (en) | 1997-02-13 | 2003-05-06 | Merck Patent Gesellschaft Mit | Bicyclic amino acids |
| DE19705450A1 (de) * | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclische aromatische Aminosäuren |
| DE19755800A1 (de) | 1997-12-16 | 1999-06-17 | Merck Patent Gmbh | Cyclopeptidderivate |
| DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| AU760246B2 (en) | 1999-02-20 | 2003-05-08 | Merck Patent Gmbh | Beta-alanine derivatives |
| DE19916837A1 (de) | 1999-04-14 | 2000-10-19 | Merck Patent Gmbh | Dibenzoazulenderivate |
| DE19932796A1 (de) | 1999-07-14 | 2001-01-18 | Merck Patent Gmbh | Diacylhydrazinderivate |
| DE19939980A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
| JP4868681B2 (ja) * | 2000-03-31 | 2012-02-01 | ザ スクリプス リサーチ インスティチュート | 血管新生の調節のために有用なヒトアミノアシル−ｔＲＮＡシンテターゼポリペプチド |
| PL204102B1 (pl) * | 2000-11-01 | 2009-12-31 | Merck Patent Gmbh | Zastosowanie inhibitorów αvß₃ i/lub αvß₅ do otrzymywania leku do profilaktyki i/lub terapii chorób oczu. |
| WO2002036142A2 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| UA75898C2 (en) * | 2000-11-14 | 2006-06-15 | Merck Patent Gmbh | Method for prophylaxis and treatment of eye diseases using antagonist of integrin receptors |
| IL152420A0 (en) * | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
| ATE420653T1 (de) * | 2001-02-23 | 2009-01-15 | Scripps Research Inst | Von tryptophanyl-trna-synthetase stammende polypeptide zur regulierung der angiogenese |
| AU2002332430A1 (en) * | 2001-07-26 | 2003-02-17 | Novartis Ag | Methods of treating neuropilin-mediated diseases |
| AP1750A (en) * | 2001-11-09 | 2007-06-23 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
| NZ535100A (en) * | 2002-03-20 | 2008-04-30 | Univ Florida | RAAV vector compositions and methods for the treatment of choroidal neovascularization |
| WO2003093303A1 (en) * | 2002-05-06 | 2003-11-13 | Board Of Regents, The University Of Texas System | Targeting proteins to deliver therapeutic or diagnostic reagents |
| WO2005020972A2 (en) * | 2003-08-27 | 2005-03-10 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of ocular neovascular disorders |
| MXPA06007269A (es) * | 2003-12-23 | 2007-07-09 | Univ Pennsylvania | Composiciones y metodos para terapia combinada de enfermedad. |
| PT1765362E (pt) * | 2004-06-04 | 2012-06-04 | Scripps Research Inst | Composições e métodos para o tratamento de doenças neovasculares |
-
2005
- 2005-06-06 PT PT05804888T patent/PT1765362E/pt unknown
- 2005-06-06 EP EP12002027.6A patent/EP2484364B1/en not_active Expired - Lifetime
- 2005-06-06 AT AT05804888T patent/ATE551060T1/de active
- 2005-06-06 EP EP12002028.4A patent/EP2484365B1/en not_active Expired - Lifetime
- 2005-06-06 PL PL12002028T patent/PL2484365T3/pl unknown
- 2005-06-06 ES ES05804888T patent/ES2382661T3/es not_active Expired - Lifetime
- 2005-06-06 WO PCT/US2005/019800 patent/WO2005117954A2/en active Application Filing
- 2005-06-06 PL PL05804888T patent/PL1765362T3/pl unknown
- 2005-06-06 DK DK12002028.4T patent/DK2484365T3/da active
- 2005-06-06 JP JP2007515675A patent/JP4943324B2/ja not_active Expired - Fee Related
- 2005-06-06 ES ES12002028.4T patent/ES2439390T3/es not_active Expired - Lifetime
- 2005-06-06 EP EP05804888A patent/EP1765362B1/en not_active Expired - Lifetime
- 2005-06-06 DK DK05804888.5T patent/DK1765362T3/da active
- 2005-06-06 CA CA2568750A patent/CA2568750C/en not_active Expired - Fee Related
- 2005-06-06 PT PT120020284T patent/PT2484365E/pt unknown
- 2005-06-06 ES ES12002027.6T patent/ES2450541T3/es not_active Expired - Lifetime
- 2005-06-06 AU AU2005249586A patent/AU2005249586B2/en not_active Ceased
- 2005-06-06 US US11/145,587 patent/US7528106B2/en not_active Expired - Fee Related
- 2005-06-06 KR KR1020077000238A patent/KR101224368B1/ko not_active Expired - Fee Related
- 2005-06-06 MX MXPA06014092A patent/MXPA06014092A/es active IP Right Grant
-
2009
- 2009-05-04 US US12/387,507 patent/US20090285792A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE551060T1 (de) | 2012-04-15 |
| WO2005117954A3 (en) | 2006-10-12 |
| ES2450541T3 (es) | 2014-03-25 |
| EP2484364A1 (en) | 2012-08-08 |
| KR101224368B1 (ko) | 2013-01-22 |
| KR20070041498A (ko) | 2007-04-18 |
| DK2484365T3 (da) | 2013-12-02 |
| CA2568750A1 (en) | 2005-12-15 |
| DK1765362T3 (da) | 2012-05-14 |
| PT2484365E (pt) | 2013-12-12 |
| MXPA06014092A (es) | 2007-03-15 |
| EP1765362A4 (en) | 2010-02-24 |
| ES2382661T3 (es) | 2012-06-12 |
| WO2005117954A2 (en) | 2005-12-15 |
| US7528106B2 (en) | 2009-05-05 |
| US20090285792A1 (en) | 2009-11-19 |
| PT1765362E (pt) | 2012-06-04 |
| EP2484365B1 (en) | 2013-10-02 |
| CA2568750C (en) | 2014-05-27 |
| JP4943324B2 (ja) | 2012-05-30 |
| EP1765362A2 (en) | 2007-03-28 |
| AU2005249586A1 (en) | 2005-12-15 |
| EP2484364B1 (en) | 2014-02-19 |
| EP2484365A1 (en) | 2012-08-08 |
| EP1765362B1 (en) | 2012-03-28 |
| JP2008501718A (ja) | 2008-01-24 |
| AU2005249586B2 (en) | 2010-12-23 |
| ES2439390T3 (es) | 2014-01-22 |
| PL2484365T3 (pl) | 2014-03-31 |
| US20060003933A1 (en) | 2006-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1765362E (pt) | Composições e métodos para o tratamento de doenças neovasculares | |
| SG166775A1 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| LUC00011I2 (pl) | ||
| WO2005063745A3 (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
| IL244727A0 (en) | Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases | |
| TW200626159A (en) | Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| WO2005011734A3 (en) | Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer | |
| MX336710B (es) | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. | |
| WO2005046593A3 (en) | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. | |
| EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
| TW200501946A (en) | Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight | |
| MXPA06002939A (es) | 6-aril-7-haloimidazo[1,2-a]pirimidinas como agentes contra el cancer. | |
| IL147416A (en) | Combined modalities for improved cancer treatment |